Last reviewed · How we verify
Ceftazidime-avibactam + Aztreonam
Ceftazidime-avibactam inhibits bacterial cell wall synthesis while avibactam protects against β-lactamase degradation, and aztreonam provides additional coverage against gram-negative bacteria including those resistant to other β-lactams.
Ceftazidime-avibactam inhibits bacterial cell wall synthesis while avibactam protects against β-lactamase degradation, and aztreonam provides additional coverage against gram-negative bacteria including those resistant to other β-lactams. Used for Complicated intra-abdominal infections, Complicated urinary tract infections, Hospital-acquired and ventilator-associated bacterial pneumonia.
At a glance
| Generic name | Ceftazidime-avibactam + Aztreonam |
|---|---|
| Sponsor | National University of Singapore |
| Drug class | β-lactam antibiotic combination with β-lactamase inhibitor |
| Target | Bacterial penicillin-binding proteins; β-lactamases |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
Ceftazidime is a third-generation cephalosporin that binds penicillin-binding proteins and inhibits bacterial cell wall cross-linking. Avibactam is a β-lactamase inhibitor that protects ceftazidime from enzymatic degradation by resistant organisms. Aztreonam is a monobactam antibiotic that also inhibits cell wall synthesis and provides synergistic coverage, particularly against multidrug-resistant gram-negative pathogens including Pseudomonas aeruginosa and Enterobacteriaceae.
Approved indications
- Complicated intra-abdominal infections
- Complicated urinary tract infections
- Hospital-acquired and ventilator-associated bacterial pneumonia
- Multidrug-resistant gram-negative bacterial infections
Common side effects
- Diarrhea
- Nausea
- Headache
- Phlebitis at infusion site
- Elevated liver enzymes
Key clinical trials
- Different Administration Regimens of CAZ-AVI in Combination With ATM for the Treatment of CR-GNB (PHASE4)
- Efficacy of Empirical Anti-Infective Therapy in Neutropenic Febrile Patients.
- Optimising TREATment for Severe Gram-Negative Bacterial Infections (PHASE4)
- Mortality of MBL-producing Enterobacteriaceae Bacteremias with the Combined Use of Ceftazidime-avibactam and Aztreonam Vs. Other Active Antibiotics. a Multicenter Target Trial Emulation.
- Ceftazidime-Avibactam Use in Critically Ill Patients With Carbapenem-Resistant Enterobacteriaceae Infections (PHASE3)
- Drug Resistance Mechanism of Enterobacteriaceae and Its Strategies (NA)
- A Trial to Evaluate the Pharmacokinetics and Safety of AVYCAZ(R) in Combination With Aztreonam (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Ceftazidime-avibactam + Aztreonam CI brief — competitive landscape report
- Ceftazidime-avibactam + Aztreonam updates RSS · CI watch RSS
- National University of Singapore portfolio CI